News and commentary about white-collar crime, enforcement, and compliance
Harry Cassin
Publisher and Editor
Andy Spalding
Senior Editor
Jessica Tillipman
Senior Editor
Bill Steinman
Senior Editor
Richard L. Cassin
Editor at Large
Elizabeth K. Spahn
Editor Emeritus
Cody Worthington
Contributing Editor
Julie DiMauro
Contributing Editor
Thomas Fox
Contributing Editor
Marc Alain Bohn
Contributing Editor
Bill Waite
Contributing Editor
Russell A. Stamets
Contributing Editor
Richard Bistrong
Contributing Editor
Eric Carlson
Contributing Editor
Six pharmas have disclosed open FCPA-related investigations.
Countries involved in the investigations include Brazil, China, Colombia, Japan, Russia, Turkey, and Greece.
All of the pharmas named the SEC as an investigating agency, and five also named the DOJ.… Continue Reading
At the 17th Annual Pharmaceutical and Medical Device Compliance Congress last month in Washington DC, Paul Hastings Partner Gary Giampetruzzi and FCPA Blog Contributing Editor Richard Bistrong exchanged perspectives on pharma compliance risks.… Continue Reading
It has been typical under PRC law for bribe takers to be punished more severely than bribe givers. The policy was to punish extortion and incentivize cooperation with government investigations. But as recent investigations into the sales practices of big pharmaceutical companies have shown, this policy may be changing.… Continue Reading